The global cardiovascular drugs market was evaluated at USD 144.11 billion in 2023 and is poised to grow from USD 149.99 billion in 2024 to USD 207.78 billion by 2033, growing at a CAGR of 4% from 2024 to 2033.
The cardiovascular drugs market is experiencing noteworthy growth, driven by the increasing prevalence of heart-related conditions such as arrhythmias, coronary artery disease, hypertension, and heart failure. One of the key reasons for this development is the work of many cardiovascular drugs that focus on the properties of the heart and blood vessels. These include drugs that directly affect the blood vessels around the heart, helping to reduce the work of the heart by lowering blood pressure. The increasing demand for these specialized treatments, combined with advances in drug formulations and the aging population, is causing the cardiovascular drugs market to expand.
FREE sample includes data points, ranging from trend analyses to estimates and forecasts@ https://www.precedenceresearch.com/sample/2037
Cardiovascular Drugs Market at a Glance
The cardiovascular drugs market is rapidly expanding, driven by the widespread use of these agents in treating a range of heart and circulatory system disorders, including hypertension, angina pectoris, heart failure, and arrhythmias. Cardiovascular drugs are one of the significant prescribed drugs because they play a key role in the treatment of diseases that affect the function of the heart. These drugs affect the heart in three main ways, by changing contractility (inotropic effects), by controlling heart rate (chronotropic effects), and by stabilizing the heart rhythm (rhythmogenic effects). The rising demand for effective treatments addressing different mechanisms of action is driving economic growth, making cardiovascular medicine a grounding of modern medicine.
· In March 2024, Bayer strengthened its pharma portfolio with the introduction of a new cardiology drug, acoramidis. Bayer acquired exclusive commercialization rights for the European markets for this highly potent selective small molecule oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR CM). A marketing authorization application was already submitted to the European Medicines Agency. This acquisition was a strategic fit with Bayer’s cardiovascular portfolio and innovation strategy.
Report Highlights
· Asia Pacific has held highest market share of around 34.17% in 2023.
· By Drug Type, the anticoagulants segment has garnered highest market share of 45.14% in 2023.
· By Route of Administration, the oral segment has captured 54.84% of revenue share in 2023.
· By Distribution Channel, the retail pharmacies segment has held largest market share of 44.78% in 2023.
· By disease indication, the hypertension segment has contributed market share of 28.97% in 2023.
Get Full Access of this report@ https://www.precedenceresearch.com/checkout/2037
Report Scope
Attribute | Details |
Cardiovascular Drugs Market Size In 2023 | USD 144.11 Billion |
Cardiovascular Drugs Market Size In 2032 | USD 207.78 Billion |
Cardiovascular Drugs Market CAGR | 4% from 2024 to 2033 |
Largest Revenue Holder Region | Asia Pacific (34.17%) |
Why is Asia Pacific is growing at fastest rate in cardiovascular drugs market?
The Asia Pacific is observed to grow at the fastest rate in cardiovascular drugs market during the forecast period, driven by a substantial population base and the increasing prevalence of cardiovascular diseases (CVDs). Although the prevalence of hypertension is lower in Asian countries compared to Western countries, the number of people affected is higher, especially in China and India. In these regions, the relationship between high blood pressure and the risk of death or stroke is weak, resulting in cardiovascular death.
· The number of CVD deaths is set to surge from 72.7 to 252.6 per 100,000 people in Asia Pacific by 2022. CVD have become the important cause of death in India, with ischemic heart disease and stroke accounting for more than 80% of deaths.
· As China’s population ages, life expectancy rises, and health expectations continue to rise, the prevalence and cost of cardiovascular diseases are also expected to increase, strengthening Asia Pacific’s leading role in the global cardiovascular market.
Major Breakthrough in the cardiovascular drugs market
· In April 2024, Johnson & Johnson announced that clinical and real-world evidence from its cardiovascular portfolio was featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24).
· In March 2024, Novo Nordisk and Cardior Pharmaceuticals announced that Novo Nordisk agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments contingent on achieving certain development and commercial milestones.
· In July 2023, Roche entered into a partnership with Alnylam Pharmaceuticals to study a promising new treatment for high blood pressure, marking a significant investment in the development of new cardiovascular medicines.
· In October 2022, Cordis, a global leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, announced its acquisition of MedAlliance, a Switzerland-based company known for its transformative drug-eluting balloons, subject to customary closing conditions including regulatory approvals.
Rising CVD in Aging Populations to Act as a Driver for the Industry
The rising prevalence of cardiovascular diseases (CVDs) because of aging populations is a significant driver of growth in the cardiovascular drugs market. Though the world’s CVD mortality rate has reduced over the past three decades, the number of deaths from CVD is increasing, mainly due to aging and a growing population. Age remains the most powerful, unmodifiable limiting factor for conditions such as heart disease, stroke, myocardial infarction, and peripheral arterial disease. While the ageing make up a small portion of the world’s population, they account for the majority of cardiovascular disease and are responsible for the growing demand for cardiovascular drugs. The prevalence of heart disease continues to increase with age, regardless of gender, indicating an increasing for cardiovascular drugs market.
We value your investment, get customization@ https://www.precedenceresearch.com/customization/2037
Side Effects of Cardiac Glycosides to Challenge the Market’s Expansion
Cardiac glycosides, although effective, present significant limitations due to their adverse effects, which constrain their cardiovascular drugs market growth. This drug can certainly cause a heart attack by disturbing the electrical conduction between the atria and ventricles. They can also cause the heart to beat abnormally by generating ectopic pulses outside the heart’s normal pacemaker, which can cause to severe conditions like as ventricular fibrillation if left untreated. Cardiac glycosides have a narrow range of therapeutic and toxic effects and must be taken with cautiousness, limiting their use and causing market expansion difficult.
Technological Advancements and Real-World Data to Offer Opportunities
The cardiovascular drugs market is rising for growth due to recent innovations in technology and the use of real-world data to rise currently licensed drugs and devices. Recent developments contain minimally invasive procedures to treat coronary artery disease and developing evidence that diabetes medicines may advantage heart health, even in the absence of diabetes. Furthermore, innovation in technology have increased the exactness of percutaneous coronary intervention (PCI), permitting a greater number of cases of coronary artery disease to be treated safely and effectively. These developments are creating new opportunities for the cardiovascular drugs market by expanding the use of existing therapies and improving outcomes for patients with heart disease.
Related Reports
· Cardiovascular Devices Market Report 2024 to 2034: https://www.precedenceresearch.com/cardiovascular-devices-market
· Cardiovascular Ultrasound Market Report 2024 to 2034: https://www.precedenceresearch.com/cardiovascular-ultrasound-market
· Cardiovascular Health Supplements Report 2024 to 2033: https://www.precedenceresearch.com/cardiovascular-health-supplements-market
· Cardiovascular Clinical Trials Market Report 2024 to 2033: https://www.precedenceresearch.com/cardiovascular-clinical-trials-market
By Drug Type
The anticoagulants segment led the cardiovascular drugs market, driven by its key role in preventing thrombotic actions across various cardiovascular conditions, including stroke prevention in atrial fibrillation and the treatment and secondary prevention of acute coronary syndrome. The main anticoagulants include unfractionated heparin, low molecular weight heparin (LMWH), and fondaparinux. Patients with acute coronary syndromes are typically treated with unfractionated heparin or low molecular weight heparin at performance; these two drugs have been shown to be equally effective in reducing mortality and myocardial infarction. The strong clinical benefits along with these treatments underscore the of cardiovascular drugs market share.
The antihypertensive drugs segment is the fastest-growing category in the cardiovascular drugs market, driven by the widespread prevalence of hypertension, often linked to high salt intake and age-related disorders. ACE inhibitors and ARBs are particularly suitable as first-line therapy for patients with heart failure and kidney disease, especially those with evidence of proteinuria. The increasing demand for these treatments means that this area is rapidly growing as more patients require effective treatment for high blood pressure and related problems.
By Application
Hypertension has emerged as the dominant segment within the cardiovascular drugs market, determined by the high prevalence and potential severity of this condition, defined as blood pressure readings of 140/90 mmHg or higher. Although lifestyle changes (such as healthy eating, being physically active, and quitting smoking) can help control high blood pressure, many patients need full quality control to do so. Although high blood pressure is often asymptomatic, untreated high blood pressure can lead to serious difficulties such as headaches, blindness, and chest pain, indicating the need for urgent treatment.
Arrhythmias and hyperlipidemia are the fastest-growing segments within the cardiovascular drugs market, driven by the rising prevalence of these conditions. Arrhythmias are characterized by unequal heartbeats caused by errors in the heart’s electrical signals and can be life-threatening. Treatment options for arrhythmias contain medications, pacemakers, and surgery, all of which are intended to control or eliminate irregular heartbeats. The extensive growth of these segments reflects the increasing need for effective treatments to manage the complex and severe symptoms associated with cardiac arrhythmias and hyperlipidemia.
By Distribution Channel
The retail stores segment dominates the cardiovascular drugs market, driven by the extensive availability and accessibility of medications through region pharmacies, large drug store chains, and supermarkets with dedicated drug departments. As the need for cardiovascular care continues to grow, pharmacies play a key role in ensuring patients have easy access to appropriate medications. It important to understand consumers thoughts and need when indicating a pharmacy because this information impacts the success and competitiveness of retailers in the pharmaceutical industry. The increasing requirement on retailers has highlighted the importance of retailers in the distribution of cardiovascular drugs.
Hospital pharmacies are undergoing significant growth in the cardiovascular drugs market, driven by the rising demand and supply of both rare and usually used medications. The main reason for this difference is the easy availability of these medications in hospitals. Pharmacists play an key role in the healthcare team, especially in medication administration and patient education, making them significant in the prevention and control of cardiovascular disease (CVD). Their expertise in managing difficult medications and educating patients makes hospital pharmacies a key location for the distribution and use of heart medications.
FINANCIAL PERFORMANCE: BAYER AG
Key Players Cardiovascular Drugs Market
§ Bristol-Myers Squibb Company
§ Bayer AG
§ Pfizer Inc.
§ Janssen Pharmaceuticals, Inc.
§ Novartis AG
§ Merck & Co.
§ AstraZeneca
§ Sanofi
§ Gilead Sciences, Inc.
§ F. Hoffmann-La Roche
Market Segmentation
- By Drug Type
- Antihypertensive
- Anticoagulants
- Antihyperlipidemic
- Antiplatelet Drugs
- Others
- By Disease Indication
- Hypertension
- Coronary Artery Disease
- Hyperlipidaemia
- Arrhythmia
- Others
- By Route of Administration
- Oral
- Parenteral
- Others
By Geography
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East & Africa (MEA)
Get Full Access of this Report@ https://www.precedenceresearch.com/checkout/2037
USA : +1 650 460 3308 | IND : +91 87933 22019 | Europe : +44 2080772818
Email@ sales@precedenceresearch.com
